Basilard BioTech
4 known investors
Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.
Investors · 4
In the news
Frequently asked questions
- What does Basilard BioTech do?
- Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.
- Who are Basilard BioTech's investors?
- Basilard BioTech's investors include Band of Angels, GENERAL INCEPTION, Paladin Capital Group, Vertical Venture Partners.